Correlation Between Vicore Pharma and Hansa Biopharma

Can any of the company-specific risk be diversified away by investing in both Vicore Pharma and Hansa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vicore Pharma and Hansa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vicore Pharma Holding and Hansa Biopharma AB, you can compare the effects of market volatilities on Vicore Pharma and Hansa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vicore Pharma with a short position of Hansa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vicore Pharma and Hansa Biopharma.

Diversification Opportunities for Vicore Pharma and Hansa Biopharma

0.33

Correlation Coefficient

Vicore Pharma  Hansa Biopharma

Weak diversification

The 3 months correlation between Vicore and Hansa is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Vicore Pharma Holding and Hansa Biopharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hansa Biopharma AB and Vicore Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vicore Pharma Holding are associated (or correlated) with Hansa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hansa Biopharma AB has no effect on the direction of Vicore Pharma i.e., Vicore Pharma and Hansa Biopharma go up and down completely randomly.

Pair Corralation between Vicore Pharma and Hansa Biopharma

Assuming the 90 days trading horizon Vicore Pharma Holding is expected to generate 0.84 times more return on investment than Hansa Biopharma. However, Vicore Pharma Holding is 1.19 times less risky than Hansa Biopharma. It trades about 0.11 of its potential returns per unit of risk. Hansa Biopharma AB is currently generating about 0.08 per unit of risk. If you would invest  633.00  in Vicore Pharma Holding on April 21, 2025 and sell it today you would earn a total of  146.00  from holding Vicore Pharma Holding or generate 23.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Vicore Pharma Holding  vs.  Hansa Biopharma AB

Vicore Pharma Holding

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Vicore Pharma Holding are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Vicore Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Hansa Biopharma AB

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Hansa Biopharma AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Hansa Biopharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vicore Pharma and Hansa Biopharma

The main advantage of trading using opposite Vicore Pharma and Hansa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vicore Pharma position performs unexpectedly, Hansa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hansa Biopharma will offset losses from the drop in Hansa Biopharma's long position.

The idea behind Vicore Pharma Holding and Hansa Biopharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.